STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:
Orexo (STO:ORXA):
KEY EVENTS DURING THE PERIOD
Net revenues amounted to MSEK 21.7 (80.3)
The loss after tax was MSEK 128.6 (loss: 20.5)
Earnings per share amounted to a loss of SEK 9.24 (loss: 1.54)
Orexo establishes a sales force in the Nordic markets by forming a joint venture with ProStrakan
The EU registration process of Rapinyl® has been referred to EMEA’s Committee for Medicinal Products for Human Use (CHMP)
